

Table.1 Summary of characteristics of the included studies

Study (years)	Dosage		Gender		Age(years)	median follow-up period (months)	Study type
	RT	TMZ	male	female			
Xiaoguang Qiu (2022)	60Gy	75 mg/m ² /d, 7d/week, 7week	12RT/14CRT	6RT/5CRT	Median 52RT/48CRT	17	RCT
van den Bent, Martin J (2021)	59±4Gy	a.75 mg/m ² /d during RT. b.4W after the end of RT, 150-200mg/d,12 cycles		Not provided		55.7	RCT
Wang, Jingjing (2021)	50-54Gy	75mg/m ² /d during RT concurrent 75 mg/m ² /d, 6W;	59RT/33CRT	47RT/28C RT	≤40: 54RT/39CRT; > 40:52RT/22CRT	70	Cohort
Hou, Yilin (2021)	54Gy	subsequent 150-200mg/m ² /day within D 1-5,5cycles	34RT/29CRT	21RT/26C RT	RT45.81±9.66/C RT44.23±9.40	6-36(follow-up period)	Case Control
Franceschi, Enrico (2019)	50-54Gy	TMZ Standard scheme	40	53	Median 39	96.1	Case Control
Gai, Xiu-juan (2016)	50-66Gy	50-100mg/d	18RT/20CRT	13RT/18C RT	Median 41RT/43CRT	33	Case Control

Abbreviations:RT =radiation therapy;TMZ=temozolomide;CRT=chemoradiotherapy;RCT: randomized controlled trials